This week’s MedTech deals highlight continued capital momentum across public and private markets, with companies advancing tumor ablation, kidney stone care, and AI-enabled monitoring technologies toward broader clinical adoption. Details follow below.
Alamar Biosciences announces pricing of upsized IPO
The gross proceeds from the offering are expected to be approximately $191.3M, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and other offering expenses.
The offering is expected to close on April 20, 2026, subject to the satisfaction of customary closing conditions.
Founder and CEO Yuling Luo
Last week’s tracker: Beacon Biosignals, E2 & more
Onward to raise $47.2M in private placement
In total, the company expects to raise approximately €40M ($47.2M) through the placement with institutional investors.
This includes the participation of EQT Life Sciences, which is expected to make a €25M ($29.5M) investment.
CEO Dave Marver
Calyxo raises $40M for kidney stone removal system
Ally Bridge Group and Janus Henderson Investors led the financing. Questa Capital, Avidity Partners and CRG participated, too. This funding adds to $50M raised in 2023.
The company also plans to use funds to advance clinical and health economic evidence generation through ongoing and future clinical studies. It also intends to support continued innovation in kidney stone care.
CEO Joe Catanese
Sonire Therapeutics raises $18M for tumor ablation platform advancement
Sonire Therapeutics has raised $18M towards supporting the ongoing clinical advancement of its non-invasive thermal ablation tumor treatment system.
The company’s Series A financing round was led by Santé Ventures, with additional participation from investors including Fast Track Initiative (FTI), Nomura SPARX Investment, and SBI Investment.
CEO Tohru Satoh
HeartBeam announces closing of $10M Puplic Offering of common stock
The company has closed its underwritten public offering of 12,500,000 shares of common stock for total gross proceeds of $10 million before deducting underwriting discounts, commissions, and offering expenses.
The closing of the offering occurred on April 16, 2026.
CEO Rob Eno
Osteoboost raises $8M to expand reach of bone density device
Osteoboost Health has closed an $8M financing round to scale manufacturing, expand clinical research and broaden commercialization of its FDA-cleared medical device designed to treat low bone density.
The round was led by Ambit Health Ventures, with participation from Emmeline Ventures, Disrupt Health Impact Fund and existing investors Esplanade Ventures and Portfolia.
CEO Laura Yecies
Wavelet Medical raises $7M for fetal brain monitoring
Wavelet Medical has raised $7M in seed funding through a partnership with venture studio Aegis Ventures.
The company will use the funds to develop the first non-invasive, AI-powered fetal EEG monitoring platform – technology designed to detect fetal brain distress in real time during labor and delivery.
Co-founder and CEO Liz Golden
AI Diagnostics secures $5M to deploy AI stethoscopes for TB detection
The company has raised R85M, roughly $4.5M to $5M, in a pre-Series A round to push forward the rollout of its AI-enabled digital stethoscope.
The financing was led by The Steele Foundation for Hope, with support from iFSP Group and the Global Innovation Fund. Early angel investors also joined the round, alongside returning backers Africa Health Ventures and Savant.
CEO Braden van Breda
